REFERENCES
- Norman M. Management of Idiopathic Membranous Nephropathy: Evidence Based Recommendation. Kidney Int. 1999; 55: S47–S55
- Llach F. Hypercoagulability, Renal Vein Thrombosis, and Other Thromboembolic Complication of Nephritic Syndrome. Kidney Int. 1985; 28: 429–439
- McCauley J., Shairo R., Ellis D., Igdal H., Tzakis A., Starzl T.E. Pivotal Trial of FK506 in the Management of Steroid-Resistant Nephritic Syndrome. Nephrol. Dial. Transplant 1993; 8(11)1286–1290
- Toshiaki M., Yasuto S., John C.G. Antithrombtic Effect of FK506 Versus Pro-Thrombotic Effect of Cyclosporin In Vivo. Transplantation 1995; 60(3)308–310
- Lai S.M., Luger A.M., Hashefi M., Ross G., Jr. De Novo Membranous Glomerulopathy in a Renal Transplant Patient Treated with FK506. The First Reported Case. International Journal of Artificial Organs. 1997; 20(7)379–382
- Koabayashi M., Muro K., Yoh K. Effects of FK506 on Experimental Membranous Glomerulonephritis Induced by Cationized Bovine Serum Albumin in Rats. Nephrol. Dial. Transplant. 1998; 13(10)2501–2508
- Ronald F., Jeffrey A., Alan G., Valantine F., Juan B. Antithrombotic Effect of FK506 vs. Cyclosporin in Cardiac Transplant Recipients: Potential Implications in Transplant Arteriopathy. The Journal of Heart and Lung Transplantation 1999; 18(12)1228–1231
- Keiju H., Junichi H., Yoshito T. FK506 Inhibits Renal Glomerular Thrombosis Induced in Rats by Nephrotoxic Serum and Lipopolysaccharide. Kidney Int. 1994; 45: 1572–1579
- Matsukawa W., Hara S., Yoshida F. Effects of a New Immunosuppressive Agent, FK506, in Rats with Heymann Nephritis. Journal of Laboratory and Clinical Medicine 1992; 119(2)116–123
- Benigni A., Morigi M., Perico N. The Effect of FK506 and CyA on Endothelial Cell Function and Renal Vascular Resistance. Transplantation 1992; 54: 775–780
- Janusz M., Arsalan A., Ewa C., Akikazu T., Michal M., Wlodzimierz, Buczko. The Effect of Tacrolimus and Cycloserine A on Peripheral Serotonergic Mechanisms in Uremic Rats. Thrombosis Research 1996; 83(2)175–181